Verition Fund Management LLC decreased its holdings in Mural Oncology plc (NASDAQ:MURA - Free Report) by 33.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 340,000 shares of the company's stock after selling 170,847 shares during the quarter. Verition Fund Management LLC owned 2.00% of Mural Oncology worth $1,064,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the business. Acadian Asset Management LLC purchased a new stake in Mural Oncology during the 2nd quarter worth about $998,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Mural Oncology during the second quarter worth about $84,000. Armistice Capital LLC purchased a new stake in shares of Mural Oncology during the second quarter worth approximately $5,300,000. Primecap Management Co. CA acquired a new stake in Mural Oncology in the second quarter valued at approximately $740,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Mural Oncology in the second quarter worth approximately $98,000. Institutional investors and hedge funds own 80.21% of the company's stock.
Insider Activity
In related news, CFO Adam D. Cutler sold 7,421 shares of the firm's stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $3.41, for a total transaction of $25,305.61. Following the transaction, the chief financial officer now owns 71,438 shares of the company's stock, valued at $243,603.58. This trade represents a 9.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.06% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have commented on MURA. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Mural Oncology in a research report on Monday, November 11th. Raymond James initiated coverage on Mural Oncology in a report on Friday, October 4th. They issued a "strong-buy" rating and a $18.00 price target for the company.
Read Our Latest Analysis on MURA
Mural Oncology Trading Down 1.5 %
Shares of NASDAQ MURA traded down $0.06 during trading hours on Monday, reaching $3.99. The stock had a trading volume of 147,798 shares, compared to its average volume of 186,467. The firm has a 50-day moving average of $3.58 and a 200-day moving average of $3.38. The firm has a market cap of $67.91 million and a price-to-earnings ratio of -0.44. Mural Oncology plc has a fifty-two week low of $2.88 and a fifty-two week high of $6.25.
About Mural Oncology
(
Free Report)
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Stories
Before you consider Mural Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mural Oncology wasn't on the list.
While Mural Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
